

Listing of Claims

1-2. Canceled

3. (Withdrawn) The method of claim 1, wherein the diabetes is Type II diabetes.

4. (Currently amended) The method of claim ~~1~~15, wherein the immunotoxin transiently reduces the subject's T cells in the blood and lymph nodes by at least one log unit.

5-7. Canceled

8. (Currently amended) The method of claim ~~1~~15, wherein the anti-T cell immunotoxin is UCHT1-CRM9.

9. Canceled

10. (Currently amended) The method of claim ~~1~~15, wherein the deoxyspergualin is administered beginning 0 to 24 hours prior to administration of the pancreatic islet cells to the recipient and continuing up to several weeks thereafter.

11. Canceled

12. (Currently amended) The method of claim ~~1~~15, wherein the immunotoxin is administered beginning at up to several hours before administration of the pancreatic islet cells and continuing up to several days thereafter.

13. (Currently amended) A method of inhibiting a rejection response of a recipient of a pancreatic islet transplant by inducing immune tolerance in the recipient, comprising administering ~~an~~ a divalent anti-CD3 diphtheria toxin binding mutant immunotoxin and deoxyspergualin during the peritransplant period, thereby transiently reducing the number of T-cell lymphocytes and promoting long-term survival of the transplant.

14. Canceled

15. (Currently amended) A method of ~~transplanting~~ transplanting pancreatic islet cells to a subject in need thereof, comprising

(a) administering to the ~~diabetic subject an~~ a divalent anti-T cell diphtheria toxin immunotoxin directed at the CD3-epitope anti-CD3-diphtheria toxin binding site mutant immunotoxin, thereby reducing the subject's T-cell population;

ATTORNEY DOCKET NO. 14028.0284U2
Application No. 09/810,999

- (b) administering deoxyspergualin to the subject; and
- (c) administering to the subject pancreatic islet cells from a donor.